The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
Open accessAbstract
Purpose: To evaluate the time course of therapy-induced changes in tumor glucose use during chemoradiotherapy of esophageal squamous cell carcinoma (ESCC) and to correlate the reduction of metabolic activity with histopathologic tumor response and patient survival. Patients and Methods: Thirty-eight patients with histologically proven intrathoracic ESCC (cT3, cN0/+, cM0) scheduled to undergo a 4-week course of preoperative simultaneous chemoradiotherapy followed by esophagectomy were included. Patients underwent positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) before therapy (n = 38), after 2 weeks of initiation of therapy (n = 27), and preoperatively (3 to 4 weeks after chemoradiotherapy; n = 38). Tumor metabolic activity was quantitatively assessed by standardized uptake values (SUVs). Results: Mean tumor FDG uptake before therapy was 9.3 ± 2.8 SUV and decreased to 5.7 ± 1.9 SUV 14 days after initiation of chemoradiotherapy (−38% ± 18%; P < .0001). The preoperative scan showed an additional decrease of metabolic activity to 3.3 ± 1.1 SUV (P < .0001). In histopathologic responders (< 10% viable cells in the resected specimen), the decrease in SUV from baseline to day 14 was 44% ± 15%, whereas it was only 21% ± 14% in nonresponders (P = .0055). Metabolic changes at this time point were also correlated with patient survival (P = .011). In the preoperative scan, tumor metabolic activity had decreased by 70% ± 11% in histopathologic responders and 51% ± 21% in histopathologic nonresponders. Conclusion: Changes in tumor metabolic activity after 14 days of preoperative chemoradiotherapy are significantly correlated with tumor response and patient survival. This suggests that FDG-PET might be used to identify nonresponders early during neoadjuvant chemoradiotherapy, allowing for early modifications of the treatment protocol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic principles of ROC analysis
Metz, C. E. (1978) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(78)80014-2 · Cited by 6,026
Mandard, A.-M., Dalibard, F., Mandard, J.-C., Marnay, J., Henry-Amar, M., Petiot, J.-F., Roussel, A., Jacob, J.-H., Segol, P., Samama, G., et al. (1994) · Cancer · doi:10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c · Cited by 2,044
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Bosset, J.-F., Gignoux, M., Triboulet, J.-P., Tiret, E., Mantion, G., Elias, D., Lozach, P., Ollier, J.-C., Pavy, J.-J., Mercier, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370304 · Cited by 1,376
(1992) · PubMed Central · doi:10.2967/jnumed.120.251744a · Cited by 1,172
Weber, W. A., Ott, K., Becker, K., Dittler, H.-J., Helmberger, H., Avril, N. E., Meisetschläger, G., Busch, R., Siewert, J.-R., Schwaiger, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3058 · Cited by 701
Self-citationFlamen, P., Lerut, A., Van Cutsem, E., De Wever, W., Peeters, M., Stroobants, S., Dupont, P., Bormans, G., Hiele, M., De Leyn, P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.18.3202 · Cited by 571
Mac Manus, M. P., Hicks, R. J., Matthews, J. P., McKenzie, A., Rischin, D., Salminen, E. K., & Ball, D. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.054 · Cited by 439
Smith, I. C., Welch, A. E., Hutcheon, A. W., Miller, I. D., Payne, S., Chilcott, F., Waikar, S., Whitaker, T., Ah-See, A. K., Eremin, O., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1676 · Cited by 406
Ancona, E., Ruol, A., Santi, S., Merigliano, S., Sileni, V. C., Koussis, H., Zaninotto, G., Bonavina, L., & Peracchia, A. (2001) · PubMed · doi:10.1002/1097-0142(20010601)91:11<2165::aid-cncr1245>3.0.co;2-h · Cited by 401
Cited by
Bedenne, L., Michel, P., Bouché, O., Milan, C., Mariette, C., Conroy, T., Pezet, D., Roullet, B., Seitz, J.-F., Herr, J.-P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7118 · Cited by 1,244
Weissleder, R. (2006) · Science · doi:10.1126/science.1125949 · Cited by 1,112
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
Ben-Haim, S., & Ell, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054205 · Cited by 351
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer
Swisher, S. G., Maish, M., Erasmus, J. J., Correa, A. M., Ajani, J. A., Bresalier, R., Komaki, R., Macapinlac, H., Munden, R. F., Putnam, J. B., et al. (2004) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2004.04.046 · Cited by 297
Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT
Doot, R. K., Scheuermann, J. S., Christian, P. E., Karp, J. S., & Kinahan, P. E. (2010) · Medical Physics · doi:10.1118/1.3499298 · Cited by 82
Metadata
- Authors
- Wieder, H. A., Brücher, B. L. D. M., Zimmermann, F., Becker, K., Lordick, F., Beer, A., Schwaiger, M., Fink, U., Siewert, J. R., Stein, H. J., & Weber, W. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-03-01
- Volume
- 22
- Issue
- 5
- Pages
- 900-908
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097033712
- Cited by
- 454
- References
- 30
- FWCI
- 35.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. https://app.cochat.ai/papers/10.1200/jco.2004.07.122
- The paper
- Wieder, H. A., Brücher, B. L. D. M., Zimmermann, F., Becker, K., Lordick, F., Beer, A., Schwaiger, M., Fink, U., Siewert, J. R., Stein, H. J., & Weber, W. A. (2004). Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.07.122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
